摘要
聚ADP核糖聚合酶(PARP)抑制剂是一种治疗卵巢癌的靶向生物制剂,其适用人群主要是对铂治疗敏感的卵巢癌患者。但有临床试验数据表明PARP抑制剂对铂耐药或铂难治卵巢癌患者也有一定治疗效果,未来可能成为卵巢癌患者治疗的新希望。
Poly ADP-ribose polymerase(PARP)inhibitor is a targeted biological agent for the treatment of ovarian cancer,which is mainly suitable for platinum-sensitive ovarian cancer patients.However,data from clinical trials showed that PARP inhibitors have certain therapeutic effect on platinum-resistant or platinum-refractory ovarian cancer patients.It may become a new hope for treatment of ovarian cancer patients in the future.
作者
李晨曦
赵宏伟
Li Chenxi;Zhao Hongwei(Second Clinical College,Shanxi Medical University,Taiyuan 030001,China;Second Department of Gynecology,Shanxi Provincial Cancer Hospital,Taiyuan 030001,China)
出处
《国际肿瘤学杂志》
CAS
2021年第3期180-183,共4页
Journal of International Oncology
基金
CSCO-恒瑞肿瘤研究基金(Y-HR2018-330)
山西省重点研发计划(201903D321174)。
